Monitor whether Schonfeld continues to increase its passive stake or converts to a 13D (activist) filing. The increase to 6.47% from a prior 5%+ stake suggests growing passive interest, but the passive filing indicates no intent to influence control.
Drugs in focus
INBX drug pipeline →ozekibart
▲ Bullish Named in this SC 13G/A- Impact
- Phase
- Filed/PDUFA (BLA accepted by FDA)
- Time to market
- PDUFA goal date is April14, 2027. If approved, launch could follow shortly after, positioning ozekibart as the first FDA-approved systemic therapy for conventional chondrosarcoma.
- Next catalyst
- PDUFA date · Apr 14, 2027 148d
What to watchThe next hard catalyst is the FDA PDUFA decision for ozekibart in conventional chondrosarcoma on April 14, 2027. An approval would make ozekibart the first FDA-approved systemic therapy for this rare bone cancer and likely drive a significant re-rating. A Complete Response Letter would be a severe setback given ozekibart is Inhibrx's lead asset. In the interim, watch the pace of sales under the newly filed $150M ATM equity offering and any updates on the accelerated approval pathway discussion for Ewing sarcoma.
Price Chart
REPLAYWatch the reaction play outHow similar events traded
Executive Summary
Schonfeld Strategic Advisors LLC filed an amended Schedule 13G disclosing a passive stake of 952,959 shares (6.47%) in Inhibrx Biosciences as of September 30, 2026. This is an increase from the prior initial filing, which showed a 5%+ stake, but the exact prior share count is not provided in the current filing. The filing coincides with Inhibrx's Q3 2026 earnings release, which reported a net loss of $38.7 million and cash of $199.5 million.
Key Financial Metrics
Key Facts
- Schonfeld Strategic Advisors LLC disclosed beneficial ownership of 952,959 shares of Inhibrx common stock as of September 30, 2026.
- The stake represents 6.47% of shares outstanding, based on 14,717,660 shares outstanding as of August 7, 2026.
- This is an amendment to a prior Schedule 13G filing (initial filing on August 14, 2026).
- Schonfeld is a passive investment adviser filing under Rule 13d-1(b).
- The filing was made on the same day as Inhibrx's Q3 2026 earnings release.
Financial Impact
Schonfeld holds 952,959 shares; at a $1.3B market cap (~$88 per share), the stake is valued at approximately $84 million.
Risk Factors
- Schonfeld could later convert to an activist 13D filing, signaling a more active role.
- The company's cash burn rate ($38.7M net loss in Q3) may require future capital raises, which could dilute existing shareholders.
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 3 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| SC 13G/A Filing (Primary) | 0001193805-26-001466 |
| Document: 0001193805-26-001466-index.html | 0001193805-26-001466 |
| Document: 0001193805-26-001466.txt | 0001193805-26-001466 |
Track record
22 reports on INBX
2 of 5 bullish or bearish reports moved the stock their way by T+60. Best: +29.54% at T+60 after the Jun 11, 2026 report. 6 of 12 went positive at some point.
Filters
- Nov 13, 20263d ago SC 13G/A Neutral 3/10 Viewing Entry $80.43 Now $77.66 −3.44% settles Feb 12
- Nov 13, 20263d ago S-3ASR Bearish 5/10 Entry $82.85 Now $77.66 +6.26% settles Feb 12
- Nov 13, 20263d ago Press Release Neutral 4/10 Entry $83.30 Now $77.66 −6.77% settles Feb 12
- Oct 28, 202619d ago SC 13G/A Neutral 2/10 Entry $73.29 Now $77.66 +5.96% settles Jan 26
- Oct 14, 20264w ago Insider Buy Bullish 4/10 Entry $90.50 Now $77.66 −14.19% settles Jan 12
- Sep 28, 20267w ago Insider Cluster Bullish 5/10 Entry $104.83 Now $77.66 −25.92% settles Dec 23
- Sep 17, 20268w ago Insider Cluster Bullish 5/10 Entry $109.35 Now $77.66 −28.98% settles Dec 14
- Sep 15, 20268w ago Insider Cluster Neutral 4/10 Entry $101.77 Now $77.66 −23.69% settles Dec 10
- Sep 15, 20268w ago 144 Neutral 2/10 Entry $101.77 Now $77.66 −23.69% settles Dec 10
- Sep 14, 20269w ago 144 Neutral 2/10 Entry $105.61 Now $77.66 −26.47% settles Dec 9
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers